X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-13 | JNJ | Johnson & Johnson | Swanson James D. | EVP, CIO | S - Sale+OE | $243.39 | -62,080 | 25,698 | -71% | -$15,109,759 | |||||
| D | 2026-02-17 | JNJ | Johnson & Johnson | Wolk Joseph J | EVP, CFO | S - Sale+OE | $242.80 | -89,654 | 85,008 | -51% | -$21,767,827 | |||||
| D | 2026-02-17 | JNJ | Johnson & Johnson | Reed John C | EVP, Innovative Medicine, R, D | S - Sale+OE | $243.00 | -53,931 | 10,658 | -83% | -$13,105,233 | |||||
| D | 2026-02-18 | JNJ | Johnson & Johnson | Schmid Timothy | EVP, WW Chair, MedTech | S - Sale+OE | $244.33 | -22,623 | 27,560 | -45% | -$5,527,506 | |||||
| D | 2026-02-17 | JNJ | Johnson & Johnson | Broadhurst Vanessa | EVP, Global Corp Affairs | S - Sale+OE | $243.39 | -6,197 | 23,003 | -21% | -$1,508,288 | |||||
| M | 2026-02-13 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $51.68 | -14,080 | 53,520 | -21% | -$727,646 | |||||
2026-02-13 | MPLT | Maplight Therapeutics, Inc. | Malenka Robert C. | Dir | S - Sale | $18.21 | -12,116 | 370,926 | -3% | -$220,632 | ||||||
| D | 2026-02-17 | TERN | Terns Pharmaceuticals, Inc. | Burroughs Amy L. | CEO | S - Sale+OE | $39.19 | -14,583 | 297,295 | -5% | -$571,579 | |||||
2026-02-17 | BBIO | Bridgebio Pharma, Inc. | Apuli Maricel | Chief Accounting Officer | S - Sale | $74.31 | -510 | 123,945 | 0% | -$37,898 | ||||||
2026-02-17 | BBIO | Bridgebio Pharma, Inc. | Trimarchi Thomas | Pres, CFO | S - Sale | $74.72 | -13,600 | 336,585 | -4% | -$1,016,147 | ||||||
| D | 2026-02-17 | BBIO | Bridgebio Pharma, Inc. | Scott Randal W. | Dir | S - Sale+OE | $75.46 | -10,000 | 15,589 | -39% | -$754,557 | |||||
2026-02-13 | ARVN | Arvinas, Inc. | Teel Randy | Pres, CEO | S - Sale | $11.89 | -4,403 | 154,482 | -3% | -$52,352 | ||||||
2026-02-13 | ARVN | Arvinas, Inc. | Saik Andrew | CFO | S - Sale | $11.89 | -5,134 | 159,267 | -3% | -$61,043 | ||||||
2026-02-13 | ARVN | Arvinas, Inc. | Cacace Angela M | Chief Scientific Officer | S - Sale | $11.89 | -4,592 | 151,232 | -3% | -$54,599 | ||||||
| D | 2026-02-17 | PTGX | Protagonist Therapeutics, Inc | Williams Lewis T | Dir | S - Sale+OE | $82.42 | -18,000 | 7,825 | -70% | -$1,483,560 | |||||
2026-02-13 | ARVN | Arvinas, Inc. | Berkowitz Noah | Chief Medical Officer | S - Sale | $11.89 | -5,685 | 163,938 | -3% | -$67,595 | ||||||
2026-02-13 | ARVN | Arvinas, Inc. | Loomis David K | Chief Accounting Officer | S - Sale | $11.89 | -1,016 | 30,800 | -3% | -$12,080 | ||||||
| D | 2026-02-13 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $26.49 | -200,000 | 1,654,597 | -11% | -$5,298,000 | |||||
2026-02-13 | RCKT | Rocket Pharmaceuticals, Inc. | Wilson Martin | GC | S - Sale | $3.31 | -12,253 | 683,376 | -2% | -$40,582 | ||||||
2026-02-13 | RCKT | Rocket Pharmaceuticals, Inc. | Militello John | See Remarks | S - Sale | $3.31 | -3,726 | 92,176 | -4% | -$12,341 | ||||||
2026-02-13 | RCKT | Rocket Pharmaceuticals, Inc. | Shah Gaurav | CEO | S - Sale | $3.31 | -12,279 | 1,458,283 | -1% | -$40,668 | ||||||
| D | 2026-02-17 | DAWN | Day One Biopharmaceuticals, Inc. | Merendino Lauren | Chief Commercial Officer | S - Sale+OE | $11.60 | -5,814 | 60,157 | -9% | -$67,448 | |||||
2026-02-13 | AVDL | Avadel Pharmaceuticals Plc | Weiss Asset Management LP | Former 10% Owner | S - Sale | $21.00 | -11,112,052 | 0 | -100% | -$233,353,092 | ||||||
| D | 2026-02-17 | DAWN | Day One Biopharmaceuticals, Inc. | Dubow Adam | GC, Secretary | S - Sale+OE | $11.60 | -6,395 | 72,694 | -8% | -$74,188 | |||||
| D | 2026-02-17 | DAWN | Day One Biopharmaceuticals, Inc. | York Charles N II | COO, CFO | S - Sale+OE | $11.60 | -6,065 | 312,025 | -2% | -$70,359 | |||||
| D | 2026-02-17 | DAWN | Day One Biopharmaceuticals, Inc. | Bender Jeremy | CEO | S - Sale+OE | $11.60 | -15,459 | 1,798,991 | -1% | -$179,338 | |||||
| D | 2026-02-17 | DAWN | Day One Biopharmaceuticals, Inc. | Vasconcelles Michael | Head of Research, Dev. | S - Sale+OE | $11.60 | -2,728 | 4,397 | -38% | -$31,647 | |||||
2026-02-13 | VRTX | Vertex Pharmaceuticals Inc / Ma | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $499.99 | -1,500 | 46,132 | -3% | -$749,985 | ||||||
2026-02-17 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Hodgson Ian | COO | S - Sale | $7.38 | -847 | 51,080 | -2% | -$6,253 | ||||||
2026-02-13 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Moran Sean F. | CFO | S - Sale | $7.78 | -4,701 | 96,694 | -5% | -$36,588 | ||||||
| D | 2026-02-17 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $480.75 | -22,500 | 2,648 | -89% | -$10,816,956 | |||||
| M | 2026-02-13 | LXRX | Lexicon Pharmaceuticals, Inc. | Debbane Raymond | Dir | P - Purchase | $1.31 | +268,497 | 51,408,909 | +1% | +$352,889 | |||||
| D | 2026-02-15 | MCRB | Seres Therapeutics, Inc. | Shaff Eric D. | Dir | S - Sale+OE | $8.47 | -259 | 11,577 | -2% | -$2,194 | |||||
2026-02-13 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | CEO | S - Sale | $7.78 | -13,871 | 174,316 | -7% | -$107,952 | ||||||
| D | 2026-02-15 | MCRB | Seres Therapeutics, Inc. | Young Teresa L. | See Remarks | S - Sale+OE | $8.47 | -75 | 8,557 | -1% | -$635 | |||||
| D | 2026-02-15 | MCRB | Seres Therapeutics, Inc. | Desrosier Thomas | See Remarks | S - Sale+OE | $8.47 | -78 | 7,789 | -1% | -$661 | |||||
| D | 2026-02-15 | MCRB | Seres Therapeutics, Inc. | Henn Matthew R | See Remarks | S - Sale+OE | $8.47 | -89 | 7,677 | -1% | -$754 | |||||
2026-02-13 | VRTX | Vertex Pharmaceuticals Inc / Ma | Biller Jonathan | EVP, GC | S - Sale | $499.00 | -988 | 16,838 | -6% | -$493,012 | ||||||
2026-02-13 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bhatia Sangeeta N. | Dir | S - Sale | $500.00 | -266 | 4,299 | -6% | -$133,000 | ||||||
2026-02-13 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $63.00 | +291 | 460,335 | 0% | +$18,333 | ||||||
| D | 2026-02-15 | TEVA | Teva Pharmaceutical Industries Ltd | Francis Richard D | Pres, CEO | S - Sale+OE | $34.22 | -447,778 | 605,771 | -43% | -$15,324,799 | |||||
| A | 2026-02-02 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $58.00 | +100 | 460,044 | 0% | +$5,800 | |||||
2026-02-17 | IRON | Disc Medicine, Inc. | Khara Rahul | GC | S - Sale | $62.86 | -2,853 | 52,173 | -5% | -$179,340 | ||||||
2026-02-17 | IRON | Disc Medicine, Inc. | Stephenson Pamela | Chief Commercial Officer | S - Sale | $62.86 | -5,531 | 80,998 | -6% | -$347,679 | ||||||
| D | 2026-02-10 | ERNA | Ernexa Therapeutics Inc. | Cherington Charles | 10% | P - Purchase | $0.50 | +4,000,000 | 6,779,440 | +144% | +$2,000,000 | |||||
2026-02-17 | IRON | Disc Medicine, Inc. | Savage William Jacob | Chief Medical Officer | S - Sale | $62.86 | -3,256 | 92,589 | -3% | -$204,672 | ||||||
2026-02-17 | IRON | Disc Medicine, Inc. | Yu Jonathan Yen-Wen | COO | S - Sale | $62.86 | -3,231 | 54,324 | -6% | -$203,101 | ||||||
2026-02-17 | IRON | Disc Medicine, Inc. | Quisel John D | CEO | S - Sale | $62.86 | -13,264 | 226,064 | -6% | -$833,775 | ||||||
2026-02-12 | OCUL | Ocular Therapeutix, Inc | Notman Donald | COO | S - Sale | $9.04 | -11,446 | 366,356 | -3% | -$103,472 | ||||||
2026-02-12 | OCUL | Ocular Therapeutix, Inc | Nayak Sanjay | Chief Strategy Officer | S - Sale | $9.04 | -10,348 | 332,412 | -3% | -$93,546 | ||||||
2026-02-12 | OCUL | Ocular Therapeutix, Inc | Dugel Pravin | See Remarks | S - Sale | $9.04 | -124,882 | 3,333,193 | -4% | -$1,128,933 | ||||||
2026-02-12 | OCUL | Ocular Therapeutix, Inc | Waheed Nadia | Chief Medical Officer | S - Sale | $9.04 | -7,863 | 318,417 | -2% | -$71,082 | ||||||
2026-02-13 | ALNY | Alnylam Pharmaceuticals, Inc. | Garg Pushkal | EVP Chief R, D | S - Sale | $310.08 | -2,242 | 25,529 | -8% | -$695,201 | ||||||
2026-02-13 | ALNY | Alnylam Pharmaceuticals, Inc. | Greenstreet Yvonne | CEO | S - Sale | $310.08 | -6,958 | 86,069 | -7% | -$2,157,542 | ||||||
2026-02-13 | ALNY | Alnylam Pharmaceuticals, Inc. | Tanguler Tolga | EVP, Chief Commercial Officer | S - Sale | $310.08 | -1,959 | 31,769 | -6% | -$607,448 | ||||||
| M | 2026-02-13 | ALNY | Alnylam Pharmaceuticals, Inc. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale | $321.25 | -4,000 | 21,801 | -16% | -$1,284,980 | |||||
2026-02-13 | ALNY | Alnylam Pharmaceuticals, Inc. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $310.08 | -2,242 | 59,859 | -4% | -$695,201 | ||||||
| D | 2026-02-17 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $27.59 | -417 | 44,089 | -1% | -$11,505 | |||||
| D | 2026-02-17 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Chief Medical Officer | S - Sale+OE | $32.37 | -7,000 | 34,018 | -17% | -$226,559 | |||||
| D | 2026-02-13 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Dir | S - Sale+OE | $102.09 | -2,000 | 0 | -100% | -$204,180 | |||||
2026-02-17 | UTHR | United Therapeutics Corp | Malcolm Jan | Dir | S - Sale | $474.68 | -50 | 220 | -19% | -$23,734 | ||||||
| D | 2026-02-17 | ZTS | Zoetis Inc. | Peck Kristin C | CEO | S - Sale+OE | $127.05 | -20,000 | 102,171 | -16% | -$2,540,964 | |||||
2026-02-12 | ANIP | Ani Pharmaceuticals Inc | Mutz Christopher | HEAD OF RARE DISEASE | S - Sale | $76.55 | -7,032 | 90,163 | -7% | -$538,300 | ||||||
| M | 2026-02-12 | CLYM | Climb Bio, Inc. | Thomas Stephen Basil | Dir | S - Sale | $5.29 | -100,000 | 204,657 | -33% | -$529,129 | |||||
2026-02-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $76.80 | -500 | 67,550 | -1% | -$38,400 | ||||||
| M | 2026-02-11 | ROIV | Roivant Sciences Ltd. | Manchester Keith S | Dir | S - Sale | $26.64 | -1,225,784 | 15,127,329 | -7% | -$32,658,518 | |||||
| M | 2026-02-11 | ROIV | Roivant Sciences Ltd. | Gold Daniel Allen | Dir | S - Sale | $26.64 | -1,225,784 | 15,127,329 | -7% | -$32,658,518 | |||||
| M | 2026-02-11 | ROIV | Roivant Sciences Ltd. | Qvt Financial LP | Director by Deputization | S - Sale | $26.64 | -1,225,784 | 15,127,329 | -7% | -$32,658,518 | |||||
2026-02-13 | IONS | Ionis Pharmaceuticals Inc | Swayze Eric | EVP Research | S - Sale | $81.76 | -15,642 | 32,423 | -33% | -$1,278,914 | ||||||
2026-02-11 | IONS | Ionis Pharmaceuticals Inc | Parshall B Lynne | Dir | S - Sale | $82.72 | -5,000 | 56,344 | -8% | -$413,589 | ||||||
| DM | 2026-02-12 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $27.93 | -20,404 | 44,089 | -32% | -$569,809 | |||||
2026-02-11 | ZBIO | Zenas Biopharma, Inc. | Lu Hongbo | Dir | P - Purchase | $22.50 | +25,985 | 347,968 | +8% | +$584,663 | ||||||
| M | 2026-02-12 | ZBIO | Zenas Biopharma, Inc. | Allen Patricia L | Dir | P - Purchase | $25.16 | +19,860 | 19,860 | New | +$499,746 | |||||
2026-02-11 | PBH | Prestige Consumer Healthcare Inc. | Zerillo Jeffrey | SVP Operations | S - Sale | $65.93 | -1,000 | 41,048 | -2% | -$65,930 | ||||||
2026-02-12 | TYRA | Tyra Biosciences, Inc. | Bensen Daniel | Chief Discovery Officer | S - Sale | $32.87 | -8,000 | 146,981 | -5% | -$262,965 | ||||||
| D | 2026-02-11 | CTNM | Contineum Therapeutics, Inc. | Stengone Carmine N. | CEO, Pres | S - Sale+OE | $16.00 | -400 | 14,954 | -3% | -$6,400 | |||||
| D | 2026-02-11 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | S - Sale+OE | $16.00 | -400 | 162,894 | 0% | -$6,400 | |||||
| D | 2026-02-12 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $15.70 | -3,354 | 428,286 | -1% | -$52,658 | |||||
| D | 2026-02-11 | ANAB | Anaptysbio, Inc | Loumeau Eric J | GC | S - Sale+OE | $54.00 | -10,000 | 12,835 | -44% | -$540,000 | |||||
2026-02-11 | APLS | Apellis Pharmaceuticals, Inc. | Delong Mark Jeffrey | Chief Business, Strat Officer | S - Sale | $22.15 | -368 | 114,591 | 0% | -$8,153 | ||||||
| M | 2026-02-11 | ONCY | Oncolytics Biotech Inc | Kelly Jared | CEO | P - Purchase | $0.84 | +35,100 | 109,000 | +47% | +$29,521 | |||||
2026-02-12 | ONCY | Oncolytics Biotech Inc | Look Kirk | CFO | P - Purchase | $0.84 | +12,000 | 287,515 | +4% | +$10,104 | ||||||
2026-02-12 | ONCY | Oncolytics Biotech Inc | Pisano Wayne | Dir | P - Purchase | $0.84 | +30,000 | 492,414 | +6% | +$25,338 | ||||||
2026-02-12 | ONCY | Oncolytics Biotech Inc | Heineman Thomas Charles | Chief Medical Officer | P - Purchase | $0.83 | +12,132 | 282,818 | +4% | +$10,033 | ||||||
2026-02-12 | ONCY | Oncolytics Biotech Inc | Brown Deborah Margaret | Dir | P - Purchase | $0.85 | +25,000 | 109,851 | +29% | +$21,240 | ||||||
2026-02-12 | ONCY | Oncolytics Biotech Inc | Hagerman Allison | VP, Product Development | P - Purchase | $0.83 | +10,000 | 115,059 | +10% | +$8,298 | ||||||
| M | 2026-02-11 | ONCY | Oncolytics Biotech Inc | Seizinger Bernd R. | Dir | P - Purchase | $0.83 | +100,000 | 566,991 | +21% | +$83,454 | |||||
2026-02-11 | ONCY | Oncolytics Biotech Inc | Aromando Andrew | Chief Business Officer | P - Purchase | $0.86 | +29,600 | 55,100 | +116% | +$25,418 | ||||||
2026-02-12 | ONCY | Oncolytics Biotech Inc | Andrews Patricia S | Dir | P - Purchase | $0.86 | +35,400 | 78,128 | +83% | +$30,292 | ||||||
| DM | 2026-02-10 | RYTM | Rhythm Pharmaceuticals, Inc. | Smith Hunter C | CFO | S - Sale+OE | $100.21 | -7,071 | 118,466 | -6% | -$708,576 | |||||
2026-02-11 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Pres, CEO | S - Sale | $23.39 | -7,455 | 74,266 | -9% | -$174,372 | ||||||
2026-02-11 | LYEL | Lyell Immunopharma, Inc. | Hill Stephen J. | COO | S - Sale | $23.39 | -1,236 | 17,795 | -6% | -$28,910 | ||||||
2026-02-11 | LYEL | Lyell Immunopharma, Inc. | Lee Gary K. | Chief Scientific Officer | S - Sale | $23.39 | -1,671 | 16,938 | -9% | -$39,085 | ||||||
2026-02-10 | MPLT | Maplight Therapeutics, Inc. | Garnett Timothy John | Dir | P - Purchase | $17.89 | +14,124 | 63,649 | +29% | +$252,678 | ||||||
| M | 2026-02-10 | MPLT | Maplight Therapeutics, Inc. | Malenka Robert C. | Dir | S - Sale | $18.12 | -6,863 | 383,042 | -2% | -$124,329 | |||||
2026-02-11 | VRTX | Vertex Pharmaceuticals Inc / Ma | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $460.43 | -466 | 51,436 | -1% | -$214,560 | ||||||
2026-02-11 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bunnage Mark E. | EVP, Chief Scientific Officer | S - Sale | $460.43 | -2,021 | 12,914 | -14% | -$930,529 | ||||||
2026-02-11 | VRTX | Vertex Pharmaceuticals Inc / Ma | Biller Jonathan | EVP, GC | S - Sale | $460.43 | -1,925 | 20,819 | -8% | -$886,328 | ||||||
2026-02-11 | VRTX | Vertex Pharmaceuticals Inc / Ma | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Offi | S - Sale | $460.43 | -1,751 | 22,046 | -7% | -$806,213 | ||||||
2026-02-11 | VRTX | Vertex Pharmaceuticals Inc / Ma | Ambrose Kristen | SVP, Chief Accounting Officer | S - Sale | $460.43 | -1,376 | 10,127 | -12% | -$633,552 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |